Your browser doesn't support javascript.
loading
Transcriptomic analysis links diverse hypothalamic cell types to fibroblast growth factor 1-induced sustained diabetes remission.
Bentsen, Marie A; Rausch, Dylan M; Mirzadeh, Zaman; Muta, Kenjiro; Scarlett, Jarrad M; Brown, Jenny M; Herranz-Pérez, Vicente; Baquero, Arian F; Thompson, Jonatan; Alonge, Kimberly M; Faber, Chelsea L; Kaiyala, Karl J; Bennett, Camdin; Pyke, Charles; Ratner, Cecilia; Egerod, Kristoffer L; Holst, Birgitte; Meek, Thomas H; Kutlu, Burak; Zhang, Yu; Sparso, Thomas; Grove, Kevin L; Morton, Gregory J; Kornum, Birgitte R; García-Verdugo, José-Manuel; Secher, Anna; Jorgensen, Rasmus; Schwartz, Michael W; Pers, Tune H.
Afiliação
  • Bentsen MA; UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.
  • Rausch DM; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Mirzadeh Z; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Muta K; Barrow Neurological Institute, Phoenix, AZ, USA.
  • Scarlett JM; UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.
  • Brown JM; Chakri Naruebodindra Medical Institute, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Herranz-Pérez V; UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.
  • Baquero AF; Department of Pediatric Gastroenterology and Hepatology, Seattle Children's Hospital, Seattle, WA, USA.
  • Thompson J; UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.
  • Alonge KM; Cavanilles Institute of Biodiversity and Evolutionary Biology, University of Valencia, Valencia, Spain.
  • Faber CL; Predepartamental Unit of Medicine, Jaume I University, Castelló de la Plana, Spain.
  • Kaiyala KJ; Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
  • Bennett C; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Pyke C; UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.
  • Ratner C; UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.
  • Egerod KL; Department of Oral Health Sciences, School of Dentistry, University of Washington, Seattle, WA, USA.
  • Holst B; Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
  • Meek TH; Pathology & Imaging, Global Discovery and Development Sciences, Novo Nordisk A/S, Maaloev, Denmark.
  • Kutlu B; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Zhang Y; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Sparso T; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Grove KL; Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
  • Morton GJ; Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
  • Kornum BR; Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
  • García-Verdugo JM; Bioinformatics and Data Mining, Global Research Technologies, Novo Nordisk A/S, Maaloev, Denmark.
  • Secher A; Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
  • Jorgensen R; UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.
  • Schwartz MW; Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark.
  • Pers TH; Cavanilles Institute of Biodiversity and Evolutionary Biology, University of Valencia, Valencia, Spain.
Nat Commun ; 11(1): 4458, 2020 09 07.
Article em En | MEDLINE | ID: mdl-32895383
ABSTRACT
In rodent models of type 2 diabetes (T2D), sustained remission of hyperglycemia can be induced by a single intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1), and the mediobasal hypothalamus (MBH) was recently implicated as the brain area responsible for this effect. To better understand the cellular response to FGF1 in the MBH, we sequenced >79,000 single-cell transcriptomes from the hypothalamus of diabetic Lepob/ob mice obtained on Days 1 and 5 after icv injection of either FGF1 or vehicle. A wide range of transcriptional responses to FGF1 was observed across diverse hypothalamic cell types, with glial cell types responding much more robustly than neurons at both time points. Tanycytes and ependymal cells were the most FGF1-responsive cell type at Day 1, but astrocytes and oligodendrocyte lineage cells subsequently became more responsive. Based on histochemical and ultrastructural evidence of enhanced cell-cell interactions between astrocytes and Agrp neurons (key components of the melanocortin system), we performed a series of studies showing that intact melanocortin signaling is required for the sustained antidiabetic action of FGF1. These data collectively suggest that hypothalamic glial cells are leading targets for the effects of FGF1 and that sustained diabetes remission is dependent on intact melanocortin signaling.
Assuntos
Diabetes Mellitus Experimental/dietoterapia; Diabetes Mellitus Tipo 2/tratamento farmacológico; Fator 1 de Crescimento de Fibroblastos/administração & dosagem; Hipoglicemiantes/administração & dosagem; Hipotálamo/efeitos dos fármacos; Proteínas Recombinantes/administração & dosagem; Proteína Relacionada com Agouti/metabolismo; Animais; Astrócitos/efeitos dos fármacos; Astrócitos/metabolismo; Glicemia/análise; Comunicação Celular; Núcleo Celular/efeitos dos fármacos; Núcleo Celular/metabolismo; Diabetes Mellitus Experimental/sangue; Diabetes Mellitus Experimental/etiologia; Diabetes Mellitus Experimental/patologia; Diabetes Mellitus Tipo 2/sangue; Diabetes Mellitus Tipo 2/etiologia; Diabetes Mellitus Tipo 2/patologia; Dieta Hiperlipídica/efeitos adversos; Sacarose Alimentar/administração & dosagem; Sacarose Alimentar/efeitos adversos; Humanos; Hipotálamo/citologia; Hipotálamo/patologia; Injeções Intraventriculares; Leptina/genética; Masculino; Melanocortinas/metabolismo; Hormônios Estimuladores de Melanócitos/administração & dosagem; Camundongos; Camundongos Knockout; Neurônios/efeitos dos fármacos; Neurônios/metabolismo; Oligodendroglia/efeitos dos fármacos; Oligodendroglia/metabolismo; RNA-Seq; Receptor Tipo 4 de Melanocortina/genética; Receptores de Melanocortina/antagonistas & inibidores; Receptores de Melanocortina/metabolismo; Indução de Remissão/métodos; Transdução de Sinais/efeitos dos fármacos; Análise de Célula Única; Técnicas Estereotáxicas; Transcriptoma/efeitos dos fármacos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes / Fator 1 de Crescimento de Fibroblastos / Diabetes Mellitus Experimental / Diabetes Mellitus Tipo 2 / Hipoglicemiantes / Hipotálamo Tipo de estudo: Etiology_studies / Prognostic_studies Idioma: En Revista: Nat Commun Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes / Fator 1 de Crescimento de Fibroblastos / Diabetes Mellitus Experimental / Diabetes Mellitus Tipo 2 / Hipoglicemiantes / Hipotálamo Tipo de estudo: Etiology_studies / Prognostic_studies Idioma: En Revista: Nat Commun Ano de publicação: 2020 Tipo de documento: Article